| Property | Value |
|---|
|
?:abstract
|
-
OBJECTIVES: The pandemic caused by the new SARS / Cov-2 Coronavirus represents an unprecedented scenario in modern medicine that affects many aspects of daily healthcare Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) has a high prevalence and is related to high consumption of health resources For this reason, we performed a revision of the management of LUTS and HBP during and after COVID-19 pandemic MATERIAL AND METHODS: A group of experts in benign prostatic hyperplasia from different regions of Spain were selected to design a strategy to reorganize the management of benign prostatic hyperplasia and lower urinary tract symptoms during the pandemic A comprehensive review of the literature was undertaken and a set of recommendations are generated RESULTS: Recommendations for the management of LUTS-BPH during and after the SARS/CoV2 coronavirus pandemic outbreak consist of promoting telemedicine and developing joint protocols with Primary Care Attention Clear diagnostic and treatment criteria and referral criteria must be established Referral of patients for risk complications such as kidney failure, recurrent hematuria and obstructive uropathy are a priority Surgeries due to BPH are generally potentially delayed until phases I and II of the pandemic, in which the percentage of hospitalized patients with COVID-19 does not exceed 25%, and it is necessary to determine COVID19 negativity The surgical technique that associates the least complications and the shortest stay should be selected CONCLUSIONS: The diagnosis and prescription of treatment for BPH during the COVID-19 pandemic should be based on telemedicine and joint protocols for primary care attention and urology Elective surgical treatment can be delayed until we are in phases I or II, individualizing the surgical and anaesthetic technique of choice to minimize risks OBJETIVOS: La pandemia causada por el nuevo Coronavirus SARS/Cov-2 supone un escenario sin precedentes en la medicina moderna que afecta de manera indirecta en numerosos aspectos de nuestra actividad diaria como sanitarios La hiperplasia benigna de prostata (HBP) es una patologia con una elevada prevalencia y consumo de recursos sanitarios Por ello, es necesaria una revision en el manejo de la misma con el fin de adecuarlo a las necesidades impuestas por los acontecimientos recientes MATERIAL Y METODOS: Un grupo de expertos en hiperplasia benigna de prostata de distintas comunidades autonomas de Espana fueron contactados para disenaruna estrategia para reorganizar el manejo de la hiperplasia benigna de prostata y los sintomas del tracto urinario inferior durante la pandemia Se realiza una revision narrativa de la literatura publicada y se generan una serie de recomendaciones de manejo RESULTADOS: Entre las recomendaciones para el manejo de HBP en tiempos de pandemia por coronavirus SARS/CoV2 se incluyen la promocion de teleconsulta y la realizacion de protocolos conjuntos con Atencion Primaria estableciendo criterios de diagnostico, tratamiento y derivacion claros y homogeneos Deben priorizarse las derivaciones pacientes complicaciones de riesgo tales como insuficiencia renal, hematuria recidivante y uropatia obstructiva Desde el punto de vista quirurgico, se trata generalmente de cirugias potencialmente demorables hasta fases I y II de la pandemia, donde el porcentaje de pacientes hospitalizados con Covid-19 no supera el 25%, siendo preciso determinar negatividad de COVID19 Debe seleccionarse la tecnica quirurgica que asocie una menor tasa de complicaciones asi como una estancia mas baja CONCLUSIONES: El diagnostico y el inicio del tratamiento medico de la HBP durante la pandemia debe basarse en la instauracion de la telemedicina y protocolos conjuntos con atencion primaria y urologia El tratamiento quirurgico electivo se puede demorar hasta encontrarnos en fases I o II, individualizando la tecnica quirurgica y anestesica de eleccion para minimizar riesgos
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Archivos_espanoles_de_urologia
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Benign prostatic hyperplasia management during COVID-19 pandemia./ Manejo de la hiperplasia benigna de prostata durante la pandemia COVID-19
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}